Skip to main content

Table 3 Outcomes within 30 days of receiving tocilizumab

From: Effects of Tocilizumab in COVID-19 patients: a cohort study

n (%) All Received steroids No steroids p-value
Clinical improvement 36/60 (60.0) 13/36 (36.1%) 23/36 (63.9%) 0.0015
 WHO ordinal scale on day of tocilizumab administration, median (range) 4 (3–7) 4 (4–7) 4 (3–7) 0.47
 WHO ordinal scale on day 30, median (range) 1 (1–4) 1 (1–4) 1 (1–4)  -
Mortality 9/60 (15.0) 5/9 (55.6%) 4/9 (44.4%) 1.00
 Time to death from receiving tocilizumab, median days (range) 6 (1–14)    
Discharged alive 33/60 (55.0) 15/33 (45.5%) 18/33 (54.5%) 0.27
 Hospital length of stay, median days (range) 15 (0–32)    
Required ICU care 52/60 (86.7) 31/52 (59.6%) 21/52 (40.4%) 0.02
 Remained admitted to ICU at day 30 13/52 (25.0)    
 Step down to floor at day 30 5/52 (9.6)    
 Discharged from hospital alive by day 30 25/52 (48.1)    
 Died by day 30 9/52 (17.3)    
Required invasive mechanical ventilation 29/60 (48.3) 19/29 (65.5%) 10/29 (34.5%) 0.12
Successful extubation 13/29 (44.8) 7/13 (53.8%) 6/13 (46.2%) 0.27
 Duration of mechanical ventilation, median days (range) 15 (6–35)    
Infectious complications 16/60 (26.7) 10/16 (62.5%) 6/16 (37.5%) 0.57
 Time to first infection, median days (range) 10.5 (2–28)    
 Cultures drawn while in ICU, n (%) 26/29 (89.7)    
 Cultures drawn while intubated, n (%) 25/29 (86.2)    
 Type of infection, n (%)
  Respiratory 14/29 (48.3)    
  Bloodstream 14/29 (48.3)    
  Urinary 1/29 (3.4)